Citations 2
Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer
Block, Matthew S. , Charbonneau, Bridget, Vierkant, Robert A. , Fogarty, Zachary C. , Bamlet, William R. , Chenevix-Trench, Georgia, AOCS, for, Group, /ACS, Rossing, Mary Anne, Cramer, Daniel, Pearce, Celeste Leigh, Schildkraut, Joellen, Menon, Usha , Kjær, Susanne K. , Levine, Douglas A. , Culver, Hoda Anton, Whittemore, Alice S. , Lambrechts, Diether , Wentzensen, Nicolas , Kupryjańczyk, Jolanta , Chang‐Claude, Jenny , Bandera, Elisa V. , Høgdall, Estrid , Heitz, Florian , Kaye, Stanley B., Fasching, Peter A. , Campbell, Ian , Goodman, Marc T. , Bean, Yukie T., Hays, Laura E., Lurie, Galina, Eccles, Diana , Hein, Alexander , Beckmann, Matthias W. , Ekici, Arif B. , Paul, James, Brown, Robert , Flanagan, James M. , Harter, Philipp , Schwaab, Ira, Høgdall, Claus , Lundvall, Lene, Olson, Sara H. , Orlow, Irene , Paddock, Lisa E. , Eilber, Ursula, Dansonka‐Mieszkowska, Agnieszka , Rzepecka, Iwona K. , Ziółkowska-Seta, Izabela, Brinton, Louise A. , García‐Closas, Montserrat , Despierre, Evelyn, Lambrechts, Sandrina, Vergote, Ignace , Walsh, Christine , Lester, Jenny, Sieh, Weiva , McGuire, Valerie , Rothstein, Joseph H. , Ziogas, Argyrios, Lubiński, Jan , Menkiszak, Janusz , Jensen, Allan , Gayther, Simon A. , Ramus, Susan J. , Wu, Anna H. , Pike, Malcolm C. , Terry, Kathryn L. , Vitonis, Allison F., Ramirez, Starr M., Rider, David N., Knutson, Keith L. , Sellers, Thomas A. , Phelan, Catherine M., Johnatty, Sharon E., DeFazio, Anna , Song, Honglin , Kalli, Kimberly R., Cunningham, Julie M. , Goode, Ellen L. , Chenevix‐Trench, Georgia , Lambrechts, Diether , Pharoah, Paul D.P. , Chenevix-Trench, Georgia, AOCS, for, Group, /ACS, Gronwald, Jacek , Karlan, Beth Y. , Pejovic, Tanja B. , Bois, Andreas du , Rudolph, Anja , Yang, Hannah , Lester, Jenny, Cybulski, Cezary , Gentry‐Maharaj, Aleksandra , Berchuck, Andrew , Berg, David Van Den , Knutson, Keith L. , Doherty, Jennifer A. , Tyrer, Jonathan P. , Fridley, Brooke L. , Fazio, Anna de , Lambrechts, Diether , Kjaer, Susanne K , Ramus, Susan J , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Orlow, Irene , Campbell, Ian G , Bamlet, William R , Menkiszak, Janusz , Brown, Robert , Fogarty, Zachary C , Flanagan, James M , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , García-Closas, Montserrat , Ekici, Arif B , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T , Bandera, Elisa V.
Cancer Epidemiology, Biomarkers & Prevention | April 17, 2014 | Volume: 23 | Issue: 7 | Pages: 1421-1427
Abstract Survival in epithelial ovarian cancer (EOC) is influenced by the host immune response, yet the key genetic determinants of inflammation and immunity that affect prognosis are not known. The nuclear factor-κB (NF-κB) transcription factor family plays an important role in many immune and inflammatory responses, including the response to cancer. We studied common inherited variation in 210 genes in the NF-κB family in 10,084 patients with invasive EOC (5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous) from the Ovarian Cancer Association Consortium. Associations between genotype and overall survival were assessed using Cox regression for all patients and by major histology, adjusting for known prognostic factors and correcting for multiple testing (threshold for statistical significance, P < 2.5 × 10−5). Results were statistically significant when assessed for patients of a single histology. Key associations were with caspase recruitment domain family, member 11 (CARD11) rs41324349 in patients with mucinous EOC [HR, 1.82; 95% confidence interval (CI), 1.41–2.35; P = 4.13 × 10−6] and tumor necrosis factor receptor superfamily, member 13B (TNFRSF13B) rs7501462 in patients with endometrioid EOC (HR, 0.68; 95% CI, 0.56–0.82; P = 2.33 × 10−5). Other associations of note included TNF receptor–associated factor 2 (TRAF2) rs17250239 in patients with high-grade serous EOC (HR, 0.84; 95% CI, 0.77–0.92; P = 6.49 × 10−5) and phospholipase C, gamma 1 (PLCG1) rs11696662 in patients with clear cell EOC (HR, 0.43; 95% CI, 0.26–0.73; P = 4.56 × 10−4). These associations highlight the potential importance of genes associated with host inflammation and immunity in modulating clinical outcomes in distinct EOC histologies. Cancer Epidemiol Biomarkers Prev; 23(7); 1421–7. ©2014 AACR.
Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome
White, Kristin L., Vierkant, Robert A. , Fogarty, Zachary C. , Charbonneau, Bridget, Block, Matthew S. , Chenevix‐Trench, Georgia , group;, for AOCS/ACS, Rossing, Mary Anne, Pearce, Celeste Leigh, Schildkraut, Joellen M. , Menon, Usha , Kjær, Susanne K. , Levine, Douglas A. , Culver, Hoda Anton, Whittemore, Alice S. , Lambrechts, Diether , Wentzensen, Nicolas , Kupryjańczyk, Jolanta , Chang‐Claude, Jenny , Bandera, Elisa V. , Høgdall, Estrid , Heitz, Florian , Kaye, Stanley B., Fasching, Peter A. , Campbell, Ian , Goodman, Marc T. , Bean, Yukie T., Lurie, Galina, Eccles, Diana , Hein, Alexander , Beckmann, Matthias W. , Ekici, Arif B. , Brown, Robert , Flanagan, James M. , Harter, Philipp , Schwaab, Ira, Høgdall, Claus , Lundvall, Lene, Olson, Sara H. , Orlow, Irene , Paddock, Lisa E. , Rudolph, Anja , Eilber, Ursula, Dansonka‐Mieszkowska, Agnieszka , Rzepecka, Iwona K. , Ziółkowska-Seta, Izabela, Brinton, Louise A. , García‐Closas, Montserrat , Despierre, Evelyn, Lambrechts, Sandrina, Vergote, Ignace , Walsh, Christine , Lester, Jenny, Sieh, Weiva , McGuire, Valerie , Rothstein, Joseph H. , Lubiński, Jan , Menkiszak, Janusz , Jensen, Allan , Gayther, Simon A. , Ramus, Susan J. , Wu, Anna H. , Pike, Malcolm C. , DenBerg, David Van, Terry, Kathryn L. , Vitonis, Allison F., Johnatty, Sharon E., DeFazio, Anna , Song, Honglin , Sellers, Thomas A. , Phelan, Catherine M., Kalli, Kimberly R., Cunningham, Julie M. , Goode, Ellen L. , Lambrechts, Diether , Pharoah, Paul D.P. , group;, for AOCS/ACS, Cramer, Daniel W. , Gronwald, Jacek , Karlan, Beth Y. , Pejovic, Tanja B. , Paul, James , Bois, Andreas du , Yang, Hannah , Ziogas, Argyrios , Cybulski, Cezary , Gentry‐Maharaj, Aleksandra , Berchuck, Andrew , Doherty, Jennifer A. , Tyrer, Jonathan P. , Fridley, Brooke L. , Fazio, Anna de , Rudolph, Anja , Lambrechts, Diether , Kjaer, Susanne K , Ramus, Susan J , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Orlow, Irene , Campbell, Ian G , Menkiszak, Janusz , Brown, Robert , Fogarty, Zachary C , Flanagan, James M , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , García-Closas, Montserrat , Ekici, Arif B , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T , Bandera, Elisa V.
Cancer Epidemiology, Biomarkers & Prevention | March 19, 2013 | Volume: 22 | Issue: 5 | Pages: 987-992
Abstract Background: Ovarian cancer is a leading cause of cancer-related death among women. In an effort to understand contributors to disease outcome, we evaluated single-nucleotide polymorphisms (SNP) previously associated with ovarian cancer recurrence or survival, specifically in angiogenesis, inflammation, mitosis, and drug disposition genes. Methods: Twenty-seven SNPs in VHL, HGF, IL18, PRKACB, ABCB1, CYP2C8, ERCC2, and ERCC1 previously associated with ovarian cancer outcome were genotyped in 10,084 invasive cases from 28 studies from the Ovarian Cancer Association Consortium with over 37,000-observed person-years and 4,478 deaths. Cox proportional hazards models were used to examine the association between candidate SNPs and ovarian cancer recurrence or survival with and without adjustment for key covariates. Results: We observed no association between genotype and ovarian cancer recurrence or survival for any of the SNPs examined. Conclusions: These results refute prior associations between these SNPs and ovarian cancer outcome and underscore the importance of maximally powered genetic association studies. Impact: These variants should not be used in prognostic models. Alternate approaches to uncovering inherited prognostic factors, if they exist, are needed. Cancer Epidemiol Biomarkers Prev; 22(5); 987–. ©2013 AACR.